Indianapolis, IN, United States of America

David F Mahoney


Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 1991-1998

Loading Chart...
4 patents (USPTO):Explore Patents

Title: David F. Mahoney: Innovator in Antibiotic Development

Introduction

David F. Mahoney is a distinguished inventor based in Indianapolis, IN, known for his significant contributions to the field of antibiotics. With a total of four patents to his name, Mahoney has made impactful strides in combating bacterial infections.

Latest Patents

One of Mahoney's most notable patents is the A82846 antibiotics, which introduce a new class of glycopeptide antibiotics. This innovative antibiotic, comprising A82846A, A82846B, and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099, and NRRL 18100. The A82846 antibiotics exhibit activity against Gram-positive bacteria that is comparable to that of vancomycin, signaling a promising advancement in antibiotic therapies.

Career Highlights

Currently, David F. Mahoney is employed at Eli Lilly and Company, a major player in the pharmaceutical industry. His role at Eli Lilly has enabled him to focus on innovative research and the development of new pharmaceutical solutions, contributing to the overall mission of enhancing patient care through effective treatments.

Collaborations

Throughout his career, Mahoney has collaborated with several esteemed colleagues, including Robert L. Hamill and Raymond C. Yao. These collaborations foster a cooperative environment that promotes innovation and pushes the boundaries of existing scientific knowledge in the field of medicine.

Conclusion

David F. Mahoney stands out as a leading inventor in the realm of antibiotics, particularly with his development of the A82846 antibiotics. His work at Eli Lilly and through collaborations with other scientists underscores his commitment to finding effective solutions to combat bacterial infections. Mahoney's inventions not only enhance our understanding of antibiotic resistance but also pave the way for future innovations in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…